摘要
目的评价单药培美曲塞二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法经病理学或细胞学确诊,一线化疗后出现复发或进展的晚期NSCLC患者23例。单药培美曲塞500 mg/m2,第1天,21 d为1个周期。完成2个周期以上化疗评价疗效和不良反应。结果 23例中无CR病例,PR 4例,SD 13例,PD 6例,有效率(CR+PR)为17.4%(4/23),临床获益率为(CR+PR+SD)73.9%(17/23),中位生存期(MST)8.3个月。不良反应主要为骨髓抑制和消化道反应。结论培美曲塞二线治疗晚期NSCLC安全有效,耐受性好。
Objective To evaluate the efficacy and adverse effects of pemetrexed as the second-line treatment for advanced non-small cell lung cancer（NSCLC）.Methods Confirmed by pathology or cytology,23 patients with advanced or progressive NSCLC after the first line chemotherapy treatment were detected.All patients were given pemetrexed 500 mg.m-2 on the first day,21 days as a cycle.The efficacy and adverse reactions of chemotherapy after 2 cycles were evaluated.Results There was no case with complete response.4 cases had partial response,13 had stable disease and 6 progressive disease.The overall response rate was 17.4%.The clinical benefit rate was 73.9%,median survival time（MST）was 8.3 months.The common adverse effects were leucopenia and gastrointestinal response.Conclusion Pemetrexed is effective and feasible as the second-line treatment for advanced NSCLC
出处
《实用癌症杂志》
2013年第3期295-297,共3页
The Practical Journal of Cancer
关键词
培美曲塞
非小细胞肺癌
化疗
Pemetrexed
Non-small cell lung cancer（NSCLC）
Chemotherapy
